research use only
Cat.No.S5992
| Related Targets | Adrenergic Receptor Estrogen/progestogen Receptor GPR Androgen Receptor Glucocorticoid Receptor ACE RAAS Progesterone Receptor Opioid Receptor PGES |
|---|---|
| Other Endogenous Metabolite Inhibitors | 4-HNE (4-Hydroxynonenal) Ademetionine (S-Adenosylmethionine) Sodium L-lactate 3-Hydroxybutyric acid (BHB acid) |
| Molecular Weight | Formula | -- |
Storage (From the date of receipt) | 3 years -20°C powder | |
|---|---|---|---|---|---|
| CAS No. | 9050-30-0 | -- | Storage of Stock Solutions |
|
|
|
In vitro |
Water : 100 mg/mL
DMSO
: Insoluble
Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Targets/IC50/Ki |
Wnt
|
References |
|---|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06052423 | Withdrawn | Extensive Stage Small Cell Lung Cancer (ES-SCLC) |
Hansoh BioMedical R&D Company |
November 30 2024 | Phase 2 |
| NCT05928078 | Not yet recruiting | Cognitive Decline |
University of Castilla-La Mancha |
September 1 2024 | Not Applicable |
| NCT06208735 | Not yet recruiting | B-Cell Leukemia|Non-Hodgkin''s Lymphoma|B-cell Acute Lymphoblastic Leukemia|Diffuse Large B Cell Lymphoma|High-grade B-cell Lymphoma|Primary Mediastinal Large B-cell Lymphoma (PMBCL)|Mantle Cell Lymphoma|B-cell Lymphoma |
British Columbia Cancer Agency |
July 1 2024 | Phase 1 |
| NCT05470322 | Not yet recruiting | Hidradenitis Suppurativa|Scarring |
Montefiore Medical Center |
June 2024 | Not Applicable |
| NCT06118281 | Not yet recruiting | Cardiovascular Risk|Acute Myocardial Infarction (AMI) |
Novo Nordisk A/S|Duke Clinical Research Institute |
June 25 2024 | Phase 3 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.